Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BSX stock price vs ABT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABT's multiple
Needs ABT P/E.
Implied fair value · at BSX's multiple
Needs BSX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BOSTON SCIENTIFIC CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Johnson & Johnson
BSX vs JNJ
Intuitive Surgical, Inc.
BSX vs ISRG
STRYKER CORP
BSX vs SYK
ZIMMER BIOMET HOLDINGS, INC.
BSX vs ZBH
Edwards Lifesciences Corp
BSX vs EW
Medtronic plc
BSX vs MDT
BECTON DICKINSON & CO
BSX vs BDX
Thermo Fisher Scientific Inc.
BSX vs TMO
DANAHER CORP /DE/
BSX vs DHR
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BSX can sustain its ~19.9% revenue growth and convert that growth into higher ROIC (narrowing the 10.9% vs ABT's 13.6%), then consider buying on weakness toward ABT-implied $52.8–$55.1 range because the current ~18% premium appears to price growth; otherwise, reduce exposure given the valuation premium and higher net leverage.
BSX is priced at $64.32, ~17.9% above ABT-implied P/E-derived price of $52.81, reflecting a premium to ABT across multiple multiples. The premium appears to price BSX's stronger revenue growth and superior gross margin, but it leaves limited margin for execution risk given higher EV/EBITDA and net leverage.
Supporting Metrics
